Table 1.
Demographic and clinical characteristics of SARD patients who received either BNT162b2 or mRNA-1273 vaccine (N=9838)
| Before propensity-score overlap weighting | After propensity-score overlap weightinga | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| Characteristic | BNT162b2 (N=5516) | mRNA-1273 (N=4322) | Standardized difference | BNT162b2 (N=5516) | mRNA-1273 (N=4322) | Standardized difference |
|
| ||||||
| Covid prior to index date (%) | 4.5 | 3.8 | 0.0322 | 4.0 | 4.0 | <0.001 |
| Age, mean (SD), y | 61 (15) | 61 (15) | 0.0039 | 61 (9) | 61 (11) | <0.001 |
| Female (%) | 74.5 | 75.8 | 0.0283 | 75.2 | 75.2 | <0.001 |
| White (%) | 81.9 | 85.2 | 0.0877 | 84.5 | 84.5 | <0.001 |
| Hispanic or Latinx ethnicity (%) | 7.1 | 5.6 | 0.0406 | 5.7 | 5.7 | <0.001 |
| Body mass index, mean (SD), kg/m2 | 28 (7) | 29 (7) | 0.0541 | 28.6 (4.2) | 28.6 (4.7) | <0.001 |
| Ever smoker (%) | 43.4 | 42.7 | 0.0131 | 43.6 | 43.6 | <0.001 |
| CCI (mean, SD) | 2.6 (3) | 2.3 (2.7) | 0.0783 | 2.5 (1.8) | 2.5 (2.1) | <0.001 |
| Rheumatic disease diagnosis (%) | ||||||
| Rheumatoid arthritis | 52.4 | 54.8 | 0.0483 | 54.1 | 54.1 | <0.001 |
| Other inflammatory arthritis | 16.9 | 17.8 | 0.0225 | 17.0 | 17.0 | <0.001 |
| Systemic lupus erythematosus | 13.5 | 11.6 | 0.0573 | 12.2 | 12.2 | <0.001 |
| Vasculitis | 6.0 | 5.7 | 0.0159 | 5.9 | 5.9 | <0.001 |
| Other rheumatic disease | 5.0 | 4.6 | 0.0187 | 4.7 | 4.7 | <0.001 |
| Multiple rheumatic diseases | 6.2 | 5.7 | 0.0250 | 6.0 | 6.0 | <0.001 |
| Immunomodulatory medications (%) | ||||||
| Conventional synthetic DMARDs | 74.0 | 73.6 | 0.0098 | 74.3 | 74.3 | <0.001 |
| Biologic DMARDs | 42.7 | 43.3 | 0.0128 | 42.5 | 42.5 | <0.001 |
| Rituximab | 2.3 | 2.3 | 0.0035 | 2.1 | 2.1 | <0.001 |
| Targeted synthetic DMARD | 6.7 | 5.7 | 0.0419 | 5.8 | 5.8 | <0.001 |
| Oral glucocorticoid | 11.4 | 9.5 | 0.0621 | 10.0 | 10.0 | <0.001 |
a
All variables listed were included in the propensity score models
CCI: Charlson Comorbidity Index; DMARD: Disease-Modifying Anti-Rheumatic Drug
Conventional synthetic DMARD: azathioprine, methotrexate, leflunomide, mycophenolic acid, mycophenolate mofetil, sulfasalazine, hydroxychloroquine, chloroquine; Biologic DMARDS: ocrelizumab, abatacept, infliximab, etanercept, adalimumab, certolizumab, golimumab, anakinra, canakinumab, mepolizumab, benralizumab, tocilizumab, sarilumab, secukinumab, ixekizumab, ustekinumab, guselkumab, belimumab, eculizumab; Targeted synthetic DMARD:tofacitinib, baricitinib, upadicinib